19 completed, 6 not yet recruiting, 2 terminated, 2 withdrawn. 11 Phase 4, 8 Phase 2, 3 Not applicable, 3 Phase 3, 2 Phase 1.
Follow crisaborole: new trials by email Literature Review of crisaborole trials Research Report on crisaborole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis: A Prospective Randomized Controlled Study. Crisaborole 2% topical ointment, tacrolimus ointment 0.1% - Psoriasis, Psoriasis Genital | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-10-25 | 2026-10-23 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks Tacrolimus, Crisaborole 2% Top Oint - Atopic Dermatitis | Not applicable | Not yet recruiting | Foundation University Islamabad | 72 | 2026-06-01 | 2026-04-09 |
| Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Placebo Cream, Crisaborole 2% Cream - Atopic Dermatitis (AD), Atopic Eczema | Phase 4 | Not yet recruiting | Jinnah Postgraduate Medical Centre | 270 | 2026-03-01 | 2026-03-06 |
| Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis Crisaborole 2% Topical Application Ointment [EUCRISA, tacrolimus 0.1% - Atopic Dermatitis | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 148 | 2026-03-01 | 2026-03-02 |
| Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. microneedling with topical crisaborole - Vitiligo | Not applicable | Not yet recruiting | Tanta University | 20 | 2025-08-01 | 2025-07-30 |
| Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis Crisaborole 2% topical ointment, Fluticasone propionate 0.05% topical cream - Atopic Dermatitis, Eczema | Not applicable | Completed | Noura Abdelmoneim Mohammed Elseessy | 40 | 2024-02-01 | 2026-04-17 |
| Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis JW-100, Eucrisa - Atopic Dermatitis | Phase 3 | Withdrawn | Applied Biology, Inc. | 2022-11-24 | 2022-12-19 | |
| Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy - Vitiligo | Phase 2 | Completed | University of Colorado, Denver | 32 | 2022-09-07 | 2024-06-12 |
| Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis Crisaborole 2%, Vehicle treatment, Accelerometry device for children - Atopic Dermatitis | Phase 4 | Terminated | Boston University | 72 | 2022-07-26 | 2025-03-14 |
| Characterizing Skin Microbiome Change in Atopic Dermatitis Crisaborole 2% Top Oint, Skin Microbiome Swabs - Atopic Dermatitis, Atopic Dermatitis Eczema | Early Phase 1 | Completed | University of California, Irvine | 20 | 2021-03-23 | 2024-02-02 |
| Skin bioMARkers for Atopic Eczema Therapy Evaluation crisaborole (2%) ointment, betamethasone valerate 0.1% cream - Atopic Eczema/Dermatitis (Non-Specific) | Phase 2 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 37 | 2020-11-20 | 2025-07-18 |
| Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis crisaborole ointment, vehicle ointment - Stasis Dermatitis | Phase 2 | Completed | Pfizer | 66 | 2020-06-26 | 2022-05-02 |
| Topical Crisaborole in Patients with Alopecia Areata Crisaborole Topical Ointment, Placebo Topical Ointment - Alopecia Areata | Phase 2 | Withdrawn | Tufts Medical Center | 2020-03-06 | 2024-10-28 | |
| Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis Crisaborole 2% Top Oint - Atopic Dermatitis | Phase 4 | Unknown | Massachusetts General Hospital | 150 | 2020-02-03 | 2021-02-24 |
| Steroid-reducing Effects of Crisaborole Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment - Atopic Dermatitis, Eczema | Phase 4 | Completed | Johns Hopkins University | 24 | 2019-12-17 | 2024-07-19 |
| Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Crisaborole - Atopic Dermatitis, Eczema | Phase 4 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 30 | 2019-10-03 | 2022-07-19 |
| Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment - Atopic Dermatitis | Completed | Clinical Research Center of the Carolinas | 16 | 2019-09-16 | 2021-04-28 | |
| Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Placebo ointment - Dermatitis, Atopic | Phase 4 | Completed | Innovaderm Research Inc. | 31 | 2019-05-21 | 2021-08-24 |
| Wearable Skin Sensors to Assess Nocturnal Scratch Behavior Crisaborole, Scratch sensor - Atopic Dermatitis | Completed | Northwestern University | 23 | 2019-04-18 | 2023-10-13 |
Showing 20 of 30. Sign in to see all of them.
Dermatitis, Atopic (19) · Psoriasis (6) · Eczema (3) · Dermatitis (2) · Vitiligo (2) · Alopecia Areata (1) · Dermatitis, Seborrheic (1) · Mandibulofacial Dysostosis (1) · Scleroderma, Localized (1) · Venous Insufficiency (1)
Pfizer (7) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Applied Biology, Inc. (1) · Boston University (1) · Cairo University (1) · Clinical Research Center of the Carolinas (1) · Duke University (1) · Foundation University Islamabad (1) · Hayat Abad Medical Complex, Peshawar (1) · Innovaderm Research Inc. (1) · Jinnah Postgraduate Medical Centre (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · Northwestern University (1) · Noura Abdelmoneim Mohammed Elseessy (1)
United States (17) · Mexico (3) · Australia (2) · Canada (2) · Egypt (2) · Pakistan (2) · United Kingdom (2) · Brazil (1) · Germany (1) · Italy (1) · Poland (1) · Sweden (1) · Switzerland (1)
Adela Cardones, MD (1) · Anna Fishbein, MD (1) · Anna Grossberg, MD (1) · Boni Elewski, MD (1) · Daniel Fonseca, MD (1) · David Rosmarin, MD (1) · Julie R Wolf, PhD, MPH (1) · Kevin C Thomas, PhD (1) · Lindsay C Strowd, MD, FAAD (1) · Michael J Cork, MB.ChB (1) · Natasha Atanaskova Mesinkovska, MD, PhD (1) · Raymond Cho, MD, PhD (1) · Robert Bissonnette, MD (1)
2018 (1), 2019 (1)